Navigation

News

Your contact person

Manager PR & Communications Jan Phillip Denkers

Filter reset
Moving forward, the Omics Hub will continue to serve as a key resource for clinicians and clinical network partners in order to drive novel research and ultimately improve personalized oncology and the treatment of patients.
Moving forward, the Omics Hub will continue to serve as a key resource for clinicians and clinical network partners in order to drive novel research and ultimately improve personalized oncology and the treatment of patients. (Image: Screenshot/Discover Oncology)

Indivumed: New Publication in Discover Oncology

Indivumed GmbH announced the fourth research publication enabled by the Indivumed Omics Hub. An interface for members of the Indivumed Global Clinical Network, the Omics ...

Read more …
Onco AI-Med meeting at Indivumed: Dr. David Kerr, Nils Schumacher, Prof. Gerry Melino, Nina Gabelia, Dr. John Marshall, Dr. Takayuki Yoshino, Prof. Hartmut Juhl, Dr. Sun Young Rha, Dr. Jesus Garcia-Foncillas, Dr. Carlos Sampaio and Dr. David Gallagher (fr
Onco AI-Med meeting at Indivumed: Dr. David Kerr, Nils Schumacher, Prof. Gerry Melino, Nina Gabelia, Dr. John Marshall, Dr. Takayuki Yoshino, Prof. Hartmut Juhl, Dr. Sun Young Rha, Dr. Jesus Garcia-Foncillas, Dr. Carlos Sampaio and Dr. David Gallagher (from left to right) (Picture: Indivumed)

Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg

Indivumed Therapeutics (“Indivumed”) welcomed members of the Oncology Alliance For Individualized Medicine (“Onco AI-Med”) to its global headquarters in Hamburg, ...

Read more …
Dr. Christian Regenbrecht, CEO of CELLphenomics (2nd from left) and Prof. Dr. Hartmut Juhl, CEO and founder of Indivumed (2nd from right) are pleased about the agreed partnership. ( Picture: © Indivumed)

Indivumed and CELLphenomics Announce Partnership

Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of ...

Read more …

Indivumed Celebrates 20th Anniversary

Indivumed GmbH (“Indivumed”) today celebrated the company’s 20th anniversary milestone. Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to ...

Read more …
Senator of Economics Affairs Michael Westhagemann (left) and Ralf Sommer, CEO of the Hamburg Investment and Development Bank (right) hand over the notification of funding to Indivumed CEO Prof. Dr. Hartmut Juhl (Image: ©BVM)

Accelerated drug development and personalised treatments for cancer

Indivumed GmbH is a biotech company with international activities and representative offices in the US, Japan, Italy and Brasil. It cooperates with numerous international research ...

Read more …
Indivumed is using nRavel™ for target discovery and drug development programs. (Picture: ©Jackie Niam/stock.adobe.com)

Indivumed Launches the nRavel AI Platform

Indivumed GmbH (“Indivumed”) today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines ...

Read more …
New Entity to Develop Therapeutics Targeting RAS Pathway Mutations in Colorectal Cancer (Picture: © Indivumed GmbH)

Indivumed Joins KHR Biotech

Indivumed GmbH (“Indivumed”) CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR ...

Read more …

Indivumed Announces Expansion

Indivumed GmbH (“Indivumed”) announced today the founding of Ix Therapeutics GmbH (“Ix Therapeutics”), a joint venture with Xlife Sciences AG (“Xlife Sciences”), which marks Indivumed’s ...

Read more …
Photo: Indivumed GmbH

Indivumed’s multi-omics database IndivuType

More than 200 participants from around the globe, including fourteen of the top 20 pharma companies, numerous biotech companies, and members from leading academic cancer ...

Read more …
Job board